NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) recently announced a pivotal shift in its board with the appointment of Luba Greenwood as Director.
This transition occurs as James J. Marino steps down after nearly a decade of dedicated service, including four years as Chairman, due to other commitments.
Greenwood’s extensive background spans roles as a board member for public life sciences companies, a Managing Partner at Binney Street Capital, and a Vice President at Roche, equipping her with significant expertise in corporate governance and strategic development.
Her arrival is timely, as Traws Pharma advances its novel respiratory antiviral therapies through Phase 1 studies and progresses its oncology strategy.
This change in leadership is poised to enhance the company’s strategic direction, potentially accelerating its pipeline development and expansion plans. Meanwhile, the company extends its gratitude to Marino, recognizing his valuable contributions and leadership throughout his tenure.
This board transition marks a noteworthy phase in Traws Pharma’s journey, signaling a commitment to innovation and growth in the biopharmaceutical landscape.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.